Characterization of glucose homeostasis and lipid profile in adult, seizure-free, epileptic patients in Asian population

European Journal of Neurology

Volumn 19, Issue 9, 2012, Pages 1228-1234

  Phabphal, K ^a   Limapichat, K ^a   Sathirapanya, P ^a   Setthawatcharawanich, S ^a   Geater, A ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Antiepileptic drug; Insulin resistance; Lipid; Thailand

Indexed keywords

CHOLESTEROL; CYTOCHROME P450; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHENYTOIN; TRIACYLGLYCEROL; VALPROIC ACID;

ADULT; ARTICLE; ASIAN; ATHEROSCLEROSIS; BLOOD SAMPLING; CALCULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DRUG EFFECT; EPILEPSY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SEROLOGY; STATISTICAL SIGNIFICANCE; THAILAND; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; EPILEPSY; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; PHENYTOIN; THAILAND; TRIGLYCERIDES; VALPROIC ACID;

EID: 84865296757     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03708.x     Document Type: Article

References (34)

1. Lopinto-Khoury C, Mintzer S. Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol 2010; 12: 300-308.
2. Cheng LS, Prasad AN, Rieder MJ. Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents. Can J Clin Pharmacol 2010; 17: e5-e46.
3. Annegers JF, Hauser WA, Shirts SB. Heart disease mortality and morbidity in patients with epilepsy. Epilepsia 1984; 25: 699-704.
4. Nikolaos T, Stylianos G, Chryssoula N, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004; 10: MT50-MT52.
5. Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009; 65: 448-456.
6. Belcastro V, Striano P. Commentary to: evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev 2009; 31: 474.
7. Eiris JM, Lojo S, Del Rio MC, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995; 45: 1155-1157.
8. Pylvänen V, Knip M, Pakarinen AJ, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003; 60: 571-574.
9. Luef G, Rauchenzauner M, Waldmann M, et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 2009; 86: 42-47.
10. Burn JF, Fedou C, Mercier J. Postprandial reactive hypoglycemia. Diabetes Metab 2000; 26: 337-351.
11. Verrotti A, Basciani F, De Rio M, Trotta D, Guido M, Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002; 17: 265-268.
12. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51: 676-685.
13. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
14. Ohnichi H, Saitoh S, Ura N, et al. Relationship between insulin resistance and accumulation of coronary risk factors. Diabetes Obes Metab 2002; 4: 388-393.
15. Prospective Studies Collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 00 vascular deaths. Lancet 2007; 370: 1829-1839.
16. Franzoni E, Govoni M, D'Addato S, et al. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia 1992; 33: 932-935.
17. Eris J, Novo-Rodriguez MI, Del Rio M, Meseguer P, Del Rio MC, Castro-Gago M. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000; 41: 1-7.
18. Kraus WE, Slentz CA. Exercise training, lipid regulation, and insulin action: a tangled web of cause and effect. Obesity (Silver Spring) 2009; 17(Suppl. 3): S21-S26.
19. Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics in epilepsy. Epilepsia 2009; 40: 1-23.
20. Kim JY, Lee HW. Metabolic and hormonal disturbances in woman with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007; 48: 1336-1370.
21. Latini G, Marcoveccho ML, Del Vecchio A, Gall F, Bertino E, Chiarelli F. Influence of environment on insulin sensitivity. Environ Int 2009; 35: 987-993.
22. Gibbons GF. The role of cytochrome P450 in the regulation of cholesterol biosynthesis. Lipids 2002; 37: 1163-1170.
23. Isojärvi JL, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446-451.
24. Tan H, Orbak Z, Kantarci M, Kocak N, Karaka L. Valproate induced insulin resistance in prepubertal girls with epilepsy. J Pediatr 2005; 18: 146-147.
25. Wieczorek-Baranowska A, Nowak A, Michalak E, et al. Effects of aerobic exercise on insulin, insulin-like growth factor-1 and insulin-like growth factor blinding protein-3 in overweight and obese postmenopausal woman. J Sports Med Phys Fitness 2011; 51: 525-532.
26. Castleden CM, Richens A. Letter: chronic phenytoin therapy and carbohydrate tolerance. Lancet 1973; 2: 966-967.
27. Callaghan N, Feely M, O'Callaghan M, et al. The effects of toxic and non-toxic serum phenytoin levels on carbohydrate tolerance and insulin levels. Acta Neurol Scand 1977; 56: 563-571.
28. Herchuelz A, Lebrun P, Sener A, Malaisse WJ. Ionic mechanism of diphenylhydantoin action on glucose-induced insulin release. Eur J Pharmacol 1981; 3: 189-197.
29. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in human. Implications for the insulin-resistant state. Diabetes Care 1996; 19: 390-393.
30. Adeli K, Tanhibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med 2001; 11: 170-176.
31. Patsch JR, Prasad S, Gotto AM Jr, Bengtsson-Olivecrona G. Post-prandial lipemia: a key for the conversion of high density lipopro-tein2 into high density lipoprotein3 by hepatic lipase. J Clin Invest 1984; 74: 2017-2023.
32. Verroti A, Manco R, Agostinelli S, Coppola G, Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010; 51: 268-273.
33. Sonmez FM, Demir E, Orem A, et al. Effects of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol 2006; 21: 70-74.
34. Yimaz E, Doşan Y, Gürgöze MK, Güngor S. Serum lipid changes during anticonvulsive treatment serum lipids in epileptic children. Acta Neurol Belg 2001; 101: 217-220.